alexa Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B (Appropriate sampling time for Response Assessment of Antiviral Therapy in Chronic Hepatitis B Patients) | Open Access Journals
ISSN: 2161-0479
Journal of Autacoids and Hormones
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B (Appropriate sampling time for Response Assessment of Antiviral Therapy in Chronic Hepatitis B Patients)

Juseop Kang1,2*, Minho Lee2
1Department of Pharmacology & Division of Molecular Therapeutics Development
2Internal Medicine, College of Medicine, Hanyang University
Corresponding Author : Juseop Kang
Professor and Director
Department of Pharmacology and Clinical Pharmacology Laboratory
Hanyang University, College of Medicine
Seoul 133-791, South Korea
Tel: 82 2 2292 0523
Fax: 82 2 2292 6686
E-mail: [email protected]
Received December 17, 2010; Accepted December 20, 2011; Published December 24, 2011
Citation: Kang J, Lee M (2011) Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B (Appropriate sampling time for Response Assessment of Antiviral Therapy in Chronic Hepatitis B Patients). Autacoids 1:e103. doi: 10.4172/2161-0479.1000e103
Copyright: © 2011 Kang J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Autacoids and Hormones

Hepatitis B virus (HBV) infection is a widespread disease that affects about 350 million people worldwide, contributing to global public health problems and 25-40% of these will die from liver cirrhosis or primary hepatocellular carcinoma [1-3]. Therapeutic tools for patients with chronic HB include the nucleoside analogue lamivudine and cytokine interferon α (IFN-α) based on several credible clinical trials [3-5]. In the study by Disenstag et al. [3] and Jonas et al. [4] provide the reliable results about antiviral agent, lamivudine that was well tolerated and suppressed serum levels of HBV DNA, viral replication marker, profoundly in patients with chronic HB in children and adult population. They conducted same sampling time for assessment of efficacy of antiviral agents about virological markers HBV DNA and hepatitis B antigen (HBeAg) and biochemical markers, serum alanine aminotransferase (ALT) in patients with HBV infection.
Consistently, because clinical observations and animal studies clearly show that abolish of HBV DNA by HBV-specific cytotoxic T lymphocytes always precedes changes of ALT level as a marker of hepatocellular inflammation and necrosis in chronic hepatitis B [4-7], we suggest to consider different profiles of serum ALT and viral HBV DNA kinetics after administration of antiviral agents in chronic HB patients to monitor responses about antiviral therapy against HBV infection. Therefore, we need to get samples with different time for assessment of viral and biochemical response after treatment with antiviral agents in patients with chronic HB.
Generally speaking, responses to antiviral agents in treatment of patients with chronic HB are usually no detection of viral concentrations such as HBV DNA using non-amplified assays, sustained loss of HBeAg with or without detection of anti-HBe. HBeAg is a viral protein produced by infected cell. It is not that its production is not directly inhibited by lamivudine, but that it is inhibited by INF-α and this response thought to represent the lysis of infected hepatic cell by the host’s immune response and changes in the serum HBeAg concentration can be reflects changes in infected hepatic cell mass [6-8]. ALT is the hepatic cytoplasmic enzyme that is released from damaged cells and a reliable indicator of the level of cell damage and death [6].
Therefore, the strategies of antiviral regimen that primary endpoint is HBeAg seroconversion (undetectable HBeAg, detectable anti-HBe, and undetectable HBV DNA) has danger of viral mutation dependent on duration of treatment and demerits of high cost. Therefore, based on difference of serum HBV clearance and ALT kinetics in patients with chronic HB, we may consider that switching regimen with potent antiviral agents as a primary drugs to reduce the viral DNA concentrations to undetectable level and agents with anti-inflammatory effect to reduce serum ALT level below upper limit of normal range of ALT rather than combined regimen with antiviral agents and INF-α or adefovir to escape the viral mutation and high cost to control patients with chronic HB.
 
 
References











Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11513
  • [From(publication date):
    January-2011 - Oct 19, 2017]
  • Breakdown by view type
  • HTML page views : 7749
  • PDF downloads :3764
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]icsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords